Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION An AdCom briefing document that overstates subgroup findings put scientific-advice briefing book in front of clinical-development physician in a 505(b)(2) program relying on literature plus a bridging study. This Pharma & Life Sciences / Pharmacovigilance close is to drop a secondary from scientific-advice briefing book, and the live options are Proceed under protocol, Pause the pathway, Escalate safety review.

DECISION Clinical-development physician in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using scientific-advice briefing book after an AdCom briefing document that overstates subgroup findings.

HYPOTHESES TO TEST 1. An AdCom briefing document that overstates subgroup findings is noise around an already-controlled Pharmacovigilance process in a 505(b)(2) program relying on literature plus a bridging study, given scientific-advice briefing book. 2. An AdCom briefing document that overstates subgroup findings is the event in scientific-advice briefing book that forces Proceed under protocol for clinical-development physician under Pharma & Life Sciences. 3. Scientific-advice briefing book shows a one-file miss after an AdCom briefing document that overstates subgroup findings, not a Pharmacovigilance program failure. 4. Scientific-advice briefing book cannot decide to drop a secondary yet after an AdCom briefing document that overstates subgroup findings; hold is the only Pharma & Life Sciences close a 505(b)(2) program relying on literature plus a bridging study can defend.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in scientific-advice briefing book after an AdCom briefing document that overstates subgroup findings. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 4. For this Pharma & Life Sciences Pharmacovigilance file, read scientific-advice briefing book against an AdCom briefing document that overstates subgroup findings and write the one fact that would move to drop a secondary for clinical-development physician.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (scientific-advice briefing book after an AdCom briefing document that overstates subgroup findings). If scientific-advice briefing book cannot force a Pharma & Life Sciences label under Pharmacovigilance, stop. If scientific-advice briefing book after an AdCom briefing document that overstates subgroup findings cannot support Proceed under protocol versus Pause the pathway on this Pharma & Life Sciences Pharmacovigilance close, clinical-development physician must state the unresolved clinical or safety evidence requirement explicitly.